SeaStar Medical

NASDAQ: ICU ↗$3.75 USD~$50M (post-1-for-10 reverse split, mid-2026) MCAP

#Acute Kidney Injury (AKI)#Hepatorenal Syndrome #Hyperinflammatory Conditions #Extracorporeal Immunomodulation #Cell-Directed Therapies

SeaStar Medical is a commercial-stage medical-device company developing the Selective Cytopheretic Device (SCD), a cell-directed extracorporeal immunomodulator that targets and neutralizes overactivated neutrophils and monocytes in hyperinflammatory conditions. The SCD received FDA Breakthrough Device designation and is being evaluated in clinical and commercial programs for adult Acute Kidney Injury (AKI) and pediatric Hepatorenal Syndrome. The company completed a 1-for-10 reverse stock split in January 2026 to maintain Nasdaq minimum bid-price compliance.

Company Info

Sector:Medical Devices / Extracorporeal Immunomodulation

Headquarters:Denver, Colorado, USA

Founded:2007

Website:www.seastarmedical.com/

Upcoming Milestones & Key Dates

Q3 2026

Corporate

Q2 2026 financial results and SCD commercial update

Clinical Development Pipeline

Selective Cytopheretic Device (SCD)

Target: Cell-directed extracorporeal immunomodulator targeting activated neutrophils/monocytes

Adult Acute Kidney Injury (AKI) requiring continuous renal replacement therapy

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SCD-Pediatric

Target: Cell-directed extracorporeal immunomodulator

Pediatric Hepatorenal Syndrome (HRS) and other hyperinflammatory conditions

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Eric Schlorff

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

Denver, CO and remote

Apply Now →